Avistone Pharmaceuticals

Four Chinese drug developers have snagged domestic approvals for first-in-class therapies, following on from a similar feat by two of their compatriot companies earlier this year. On July 2, BeBette

Many of China’s homegrown first-in-class drugs have had a hard time becoming rainmakers for their originators, with few becoming blockbusters in domestic or international sales terms. Since the first

Chinese biotech Avistone Pharmaceuticals has won full approval in China for vebreltinib (also known as bozitinib) for a rare subtype of glioblastoma, making the molecule the world’s first c-Met inhi

[Sidebar#SC145549] Biopharmaceutical companies and other life science start-ups may access $1.28bn in new venture capital available through four different sources, including Eir Venture Partners AB’s